Summary:
Study I4V-MC-JAIW is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, outpatient study evaluating the efficacy and safety of baricitinib 2-mg once daily (QD) and 1-mg QD as compared to placebo in adult patients with moderate to severe AD. The study population will include patients aged ≥18 years who have moderate to severe AD and a history of inadequate response or intolerance to existing topical therapies. The study duration will be up to 113 weeks over 3 study periods (screening, treatment, and post-treatment follow up).
Qualified Participants Must:
• Subjects must be at least 18 years old and have a diagnosis of moderate-to-severe atopic dermatitis for at least 12 months before baseline.
Qualified Participants May Receive:
Compensation for time and travel - $50 per study visit (up to $700 total)